Gobernanza BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Farmacéuticos

Tiempo real estimado Cboe BZX Otros sitios de cotización 17:19:53 13/01/2025			Varia. Cinco días.	Varia. 1 de enero.
66,36 ^USD	-1,52 %		-0,87 %	+1,15 %

04/12	BioMarin Pharmaceutical Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 10:00 AM
25/11	BIOMARIN PHARMACEUTICAL INC. : RBC Capital Markets permanece neutral	ZM

Comité Ejecutivo: BioMarin Pharmaceutical Inc.

Director

Funciones ocupadasDesde

Alexander Hardy

57 años

Chief Executive Officer	01/12/2023
President	01/12/2023

C. Guyer

63 años

Chief Tech/Sci/R&D Officer

01/05/2020

Gregory Friberg

Chief Tech/Sci/R&D Officer

30/09/2024

Humaira Serajuddin

Sales & Marketing

05/05/2022

Erin Burkhart

46 años

Comptroller/Controller/Auditor

02/05/2022

Kevin Eggan

Chief Tech/Sci/R&D Officer

05/10/2020

Amy Wireman

Human Resources Officer

01/01/2013

Stuart Bunting

Chief Tech/Sci/R&D Officer

Traci McCarty

Investor Relations Contact

Philip Lo Scalzo

Compliance Officer

22/11/2012

George Davis

54 años

General Counsel	01/03/2004
Corporate Secretary	01/03/2004

Eduardo Von Pervieux

Chief Tech/Sci/R&D Officer

25/05/2010

Brian Mueller

51 años

Director of Finance/CFO

29/01/2020

Composición del Consejo de Administración: BioMarin Pharmaceutical Inc.

Administrador

ComitésDesde

Randy Meier

66 años

Chairman	01/12/2023
Independent Dir/Board Member	13/09/2011

David Pyott

71 años

Executive Committee	07/04/2011
Governance Committee Chair
Nominating Committee Chair
Compensation Committee
Governance Committee	04/01/2016
Nominating Committee	04/01/2016
Audit Committee

Elizabeth Anderson

67 años

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee	10/07/2019
Nominating Committee	10/07/2019
Audit Committee	01/09/2022
Compensation Committee	01/09/2022

Willard Dere

71 años

Governance Committee	18/07/2016
Nominating Committee	18/07/2016
Audit Committee	19/03/2018
Governance Committee Chair	19/03/2018
Nominating Committee Chair	19/03/2018

Athena Countouriotis

53 años

Compensation Committee	10/06/2019
Governance Committee	10/06/2019
Nominating Committee	10/06/2019
Audit Committee
Compensation Committee Chair	05/03/2020

Elaine Heron

78 años

Audit Committee	13/12/2024
Governance Committee
Nominating Committee
Governance Committee Chair	13/12/2024
Nominating Committee Chair	13/12/2024

May Kin Ho

72 años

Audit Committee	01/03/2018
Governance Committee	25/06/2015
Nominating Committee	23/06/2015

Barbara Bodem

57 años

Audit Committee	01/01/2024
Governance Committee	01/01/2024
Nominating Committee	01/01/2024

Robert Hombach

59 años

Compensation Committee	20/03/2022
Audit Committee Chair	20/03/2022

Alexander Hardy

57 años

Director/Board Member

01/12/2023

Mark Enyedy

61 años

Director/Board Member	27/12/2023
Independent Dir/Board Member	27/12/2023

Últimos Nombramientos: BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. anuncia cambios en la dirección	21/08/24	CI
BioMarin Pharmaceutical nombra a Cristin Hubbard directora comercial	07/03/24	MT
Biomarin anuncia cambios en su junta directiva, efectivos a partir del 20 de mayo de 2024	07/03/24	CI
Biomarin Pharmaceutical Inc. anuncia la dimisión de Jeffrey Ajer como vicepresidente ejecutivo y director comercial, con efecto a partir del 1 de julio de 2024	11/01/24	CI
BioMarin Pharmaceutical Inc. anuncia nombramientos en el Consejo, efectivos a partir del 27 de diciembre de 2023	20/12/23	CI
El inversor activista Elliott apunta a la farmacéutica BioMarin -fuentes	07/11/23	RE
Biomarin Pharmaceutical Inc. anuncia cambios en su director general	02/11/23	CI

Más noticias

Antiguos Directivos y Administradores: BioMarin Pharmaceutical Inc.

Insider

Funciones ocupadas

DesdeHasta

Jean-Jacques Bienaimé

Director/Board Member	30/11/2023	21/05/2024
Chief Executive Officer	16/05/2005	30/11/2023
Chairman	01/06/2015	30/11/2023
President	-	30/11/2023

V. Lawlis

Director/Board Member	01/06/2007	21/05/2024
Independent Dir/Board Member	13/09/2011	21/05/2024

Dennis Joseph Slamon

Director/Board Member	21/03/2014	21/05/2024
Independent Dir/Board Member	21/03/2014	21/05/2024

Jeff Ajer

Corporate Officer/Principal	01/09/2005	20/05/2024
Sales & Marketing	01/09/2005	-
Corporate Officer/Principal	01/08/2005	-

Debra Charlesworth

Public Communications Contact

01/01/2023

Michael Grey

Director/Board Member	15/12/2005	25/05/2021
Independent Dir/Board Member	13/09/2011	25/05/2021

Alan J. Lewis

Director/Board Member	01/06/2005	27/05/2020
Independent Dir/Board Member	13/09/2011	27/05/2020

Robert Baffi

Corporate Officer/Principal

01/05/2000

04/05/2020

Dan Spiegelman

Director of Finance/CFO	30/05/2012	29/01/2020
Private Equity Investor	29/05/2012	29/01/2020

Camilla Simpson

Corporate Officer/Principal

01/04/2017

01/04/2019

Richard Ranieri

Human Resources Officer

04/09/2013

01/01/2019

Barrie J. Carter

Corporate Officer/Principal

01/02/2013

01/12/2018

Kathryn Falberg

Director/Board Member

18/07/2016

01/06/2017

Sarah Noonberg

Corporate Officer/Principal

01/08/2015

01/03/2017

Ken Bate

Director/Board Member	01/09/2010	01/01/2017
Independent Dir/Board Member	01/09/2010	01/01/2017

Dan Oppenheimer

Corporate Officer/Principal

01/07/2002

01/06/2016

Vassiliki Economides

Corporate Officer/Principal

01/03/2015

01/06/2016

Pierre LaPalme

Director/Board Member	01/01/2015	01/06/2016
Chairman	01/08/2004	01/06/2015
Independent Dir/Board Member	01/08/2004	10/05/2012

Joshua Grass

Public Communications Contact	01/01/2002	11/05/2009
Corporate Officer/Principal	11/05/2009	01/01/2016

Leonard Post

Chief Tech/Sci/R&D Officer

01/01/2010

01/01/2016

David J. Ellam

Corporate Officer/Principal

01/01/2010

01/01/2016

William Young

Director/Board Member	22/09/2010	12/11/2015
Independent Dir/Board Member	22/09/2010	12/11/2015

Edward Conner

Chief Tech/Sci/R&D Officer

01/10/2013

01/11/2014

Suyash Prasad

Corporate Officer/Principal

01/12/2010

01/02/2014

Mark Wood

Human Resources Officer	01/05/2004	01/06/2013
Public Communications Contact	13/09/2011	01/06/2013

Christopher Schelling

Corporate Officer/Principal

01/05/2006

01/10/2012

Stephen Aselage

Corporate Officer/Principal

01/07/2005

01/09/2012

Jeffrey Cooper

Director of Finance/CFO

01/10/2003

01/05/2012

Jackie Walling

Chief Tech/Sci/R&D Officer

25/05/2010

01/03/2012

Joseph Klein

Director/Board Member

01/06/2005

19/03/2010

Alejandro Dorenbaum

Chief Tech/Sci/R&D Officer

01/01/2009

Henry Fuchs

Chief Tech/Sci/R&D Officer

01/03/2009

Emil Kakkis

Chief Tech/Sci/R&D Officer

01/09/1998

27/02/2009

S. Michael Imperiale

Corporate Officer/Principal

01/01/2009

Gordon Vehar

Chief Tech/Sci/R&D Officer

28/01/2008

Bill Aliski

Corporate Officer/Principal

01/12/2005

01/01/2008

Lewis Chapman

Sales & Marketing

01/07/2007

Erich Sager

Director/Board Member

01/11/1997

01/03/2006

John Ditton

Sales & Marketing

01/01/2006

Christopher Starr

Chief Tech/Sci/R&D Officer	-	01/01/2006
Founder	01/01/1997	01/01/2006

Louis C. Drapeau

Chief Executive Officer	01/01/2004	01/06/2005
Director of Finance/CFO	01/01/2004	23/08/2005

Kim Tsuchimoto

Comptroller/Controller/Auditor	01/02/1997	01/06/2005
Treasurer	01/02/1997	01/06/2005

Vimal Srivastava

Corporate Officer/Principal

01/01/2005

Todd C. Zankel

Chief Tech/Sci/R&D Officer

01/01/1997

01/01/2005

John Urquhart

Director/Board Member

01/07/2003

01/01/2005

David Scott Geyer

Corporate Officer/Principal

01/02/2004

Robert A. Heft

Corporate Officer/Principal

01/01/2001

01/01/2004

Vijay Samant

Director/Board Member

01/01/2002

01/01/2004

Matt Patterson

Corporate Officer/Principal

01/01/1998

01/01/2004

Fredric D. Price

Chief Executive Officer	01/01/2000	01/01/2004
Chairman	01/01/2000	01/01/2004

Franz L. Cristiani

Director/Board Member

01/07/2002

Raymond Anderson

Chief Operating Officer	01/06/1998	01/01/2002
Director of Finance/CFO	01/06/1998	01/01/2001

Ansbert Gadicke

Director/Board Member

01/01/1997

01/01/2001

Amy Lea Waterhouse

General Counsel

01/01/2000

Steven Jungles

Corporate Officer/Principal

01/06/1999

Stuart J. Swiedler

Chief Tech/Sci/R&D Officer

01/06/1998

Grant W. Denison

Director/Board Member	21/03/1997	-
Chief Executive Officer	21/03/1997	01/01/2000
Founder	21/03/1997	-

Zhong Qi Shao

Corporate Officer/Principal

Steve Glass

Corporate Officer/Principal

Charles Olson

Corporate Officer/Principal

Leonid Katz

Corporate Officer/Principal

Barbara Wuebbels

Corporate Officer/Principal

Jeffrey Landau

Chief Administrative Officer

Monica Miller

Corporate Officer/Principal

Lisa M. Bell

General Counsel

Reinhard Gabathuler

Chief Tech/Sci/R&D Officer

Gwynn Williams

Director/Board Member

Bob Purcell

Public Communications Contact

13/09/2011

John Edward Ilett

Director/Board Member	-	-
General Counsel	-	-

Dawn Blessing

Corporate Officer/Principal

Philip A. Pemberton

Corporate Officer/Principal

Andria Langenberg

Chief Operating Officer	-	-
Chief Tech/Sci/R&D Officer	-	-

Valerie Smith

Corporate Officer/Principal

Mary Newman

General Counsel

Kevin Scott

Corporate Officer/Principal

Simrat Randhawa

Chief Tech/Sci/R&D Officer

Distribución por Edad de los Ejecutivos

Paridad de género

Hombre	21
Mujer	8

De los cuales Comité Ejecutivo

Hombre	9
Mujer	4

De los cuales Directores

Hombre	9
Mujer	2

ESG MSCI

BBB

ESG

Medio ambiente

Social

Gobernanza

Polémica

BioMarin Pharmaceutical Inc. (BioMarin) es una empresa de biotecnología que se dedica a desarrollar y comercializar terapias que abordan la raíz de las afecciones genéticas. Los productos comerciales de BioMarin incluyen Vimizim (elosulfasa alfa), Naglazyme (galsulfasa), Palynziq (pegvaliase-pqpz), Brineura (cerliponasa alfa), Aldurazyme (laronidasa), Roctavian (valoctocogene roxaparvovec), Kuvan (dihidrocloruro de sapropterina) y Voxzogo (vosoritide). El Vimizim es una terapia de sustitución enzimática para el tratamiento de la MPS IVA, un trastorno por almacenamiento lisosómico. El Roctavian es una terapia génica con vectores de virus adenoasociados (AAV5) diseñada para restablecer las concentraciones plasmáticas del factor VIII en pacientes con hemofilia A grave. El Voxzogo es un análogo del péptido natriurético tipo C (CNP) que se inyecta una vez al día para el tratamiento de la acondroplasia. Brineura es una tripeptidil peptidasa 1 (TPP1) humana recombinante para el tratamiento de pacientes con CLN2, una forma de la enfermedad de Batten.

Empleados

3.401

Sector

Farmacéuticos

Agenda

18:00 - JP Morgan Healthcare Conference

Más información sobre la empresa